Enteroviruses, hygiene and type 1 diabetes: Toward a preventive vaccine

Reviews in Medical Virology

Volumn 25, Issue 1, 2015, Pages 19-32

  Drescher, Kristen M ^a   von Herrath, Matthias ^b,c   Tracy, Steven ^d  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NovoNordisk T1D R and D Center   (United States)

^c La Jolla Spine Institute   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; COXSACKIE VIRUS B; ENTEROVIRUS; ENTEROVIRUS INFECTION; HUMAN; HYGIENE; IMMUNITY; IMMUNOMODULATION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; POLIOMYELITIS; REGULATORY T LYMPHOCYTE; REVIEW; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION; WATER SUPPLY; ANIMAL; DIABETES MELLITUS, TYPE 1; ENTEROVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; MOUSE; PHYSIOLOGY; VIROLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 1; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; HUMANS; HYGIENE; MICE; VIRAL VACCINES;

EID: 84920989016     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1815     Document Type: Review

References (136)

1. Pallansch M, Oberste MS, Whitton JL. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In Knipe DM, Howley PM (eds) Fields Virology. Wolters Kluwer, Philadelphia, 2013; 490-530.
2. Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006; 344: 9-16.
3. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genetics 2009; 41: 703-707.
4. Bluestone JA, Herold K, Eisenbarth GS. Genetics, pathogenesis, and clinical interventions in type 1 diabetes/. Nature 2010; 464: 1293-1300.
5. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. The Journal of Clinical Investigation 2006; 116: 1371-1381.
6. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. American Journal of Medical Genetics 2002; 115: 18-29.
7. Chapman NM, Coppieters K, von Herrath M, Tracy S. The microbiology of human hygiene and its impact on type 1 diabetes. Islets 2012; 4: 253-261.
8. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23: 1516-1526.
9. Knip M, Akerblom HK. Environmental factors in the pathogenesis of type 1 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association 1999; 107(Suppl 3): S93-100.
10. Craig ME, Stein H, Rawlinson WD. Viruses and type 1 diabetes: a new look at an old story. Ped Diabetes 2013; 14: 149-158.
11. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ (Clinical research ed) 2011; 342: d35.
12. Caverly C. Preliminary report of an epidemic of paralytic disease occurring in Vermont in the summer of 1894. Yale Medicine Journal 1894; 1: 1-5.
13. Paul JR. A History of Poliomyelitis. Yale University Press, 1978.
14. Minor PD. Poliovirus. In Viral Pathogenesis, Nathanson N (ed). Lippincott-Raven: Philadelphia, 1996; 555-574.
15. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. American Journal of Epidemiology 1979; 110: 672-692.
16. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology 2010; 172: 1213-1229.
17. Lavinder C, Freeman A, Frost W. Epidemiologic studies of poliomyelitis in New York City and the northeastern United States during the year 1916. US GPO, Washington, D.C., 1918.
18. Martino TA, Tellier R, Petric M, Irwin DM, Afshar A, Liu PP. The complete consensus sequence of coxsackievirus B6 and generation of infectious clones by long RT-PCR. Virus Research 1999; 64: 77-86.
19. Oikarinen S, Tauriainen S, Hober D, Lucas B, Vazeou A, Sioofy-Khojine A, Bozas E, Muir P, Honkanen H, Ilonen J, Knip M, Keskinen P, Saha MT, Huhtala H, Stanway G, Bartsocas C, Ludvigsson J, Taylor K, Hyoty H. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes 2014; 63: 655-662.
20. Goldwater P. Immunoglobulin M capture immunoassay in investigation of coxsackievirus B5 and B6 outbreaks in South Australia. Journal of Clinical Microbiology 1995; 33: 1628-1631.
21. Tapparel C, Junier T, Gerlach D, Van-Belle S, Turin L, Cordey S, Muhlemann K, Regamey N, Aubert JD, Soccal PM, Eigenmann P, Zdobnov E, Kaiser L. New respiratory enterovirus and recombinant rhinoviruses among circulating picornaviruses. Emerging Infectious Diseases 2009; 15: 719-726.
22. Tapparel C, Siegrist F, Petty TJ, Kaiser L. Picornavirus and enterovirus diversity with associated human diseases. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 2013; 14: 282-293.
23. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. The Journal of Infectious Diseases 1974; 129: 304-309.
24. Klemola P, Kaijalainen S, Ylipaasto P, Roivainen M. Diabetogenic effects of the most prevalent enteroviruses in Finnish sewage. Annals of the New York Academy of Sciences 2008; 1150: 210-212.
25. Roivainen M, Knip M, Hyoty H, Kulmala P, Hiltunen M, Vahasalo P, Hovi T, Akerblom HK. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Journal of Medical Virology 1998; 56: 74-78.
26. Salvatoni A, Baj A, Bianchi G, Federico G, Colombo M, Toniolo A. Intrafamilial spread of enterovirus infections at the clinical onset of type 1 diabetes. Pediatric Diabetes 2013; 14: 407-416.
27. Smura T, Ylipaasto P, Klemola P, Kaijalainen S, Kyllonen L, Sordi V, Piemonti L, Roivainen M. Cellular tropism of human enterovirus D species serotypes EV-94, EV-70, and EV-68 in vitro: implications for pathogenesis. Journal of Medical Virology 2010; 82: 1940-1949.
28. Ylipaasto P, Klingel K, Lindberg AM, Otonkoski T, Kandolf R, Hovi T, Roivainen M. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 2004; 47: 225-239.
29. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Li Q. An inactivated enterovirus 71 vaccine in healthy children. The New England Journal of Medicine 2014; 370: 829-837.
30. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. The New England Journal of Medicine 2014; 370: 818-828.
31. Rowlands DJ, Minor PD. Vaccine strategies. In The Picornaviruses, Ehrenfeld E, Domingo E, Roos R (eds). ASM Press, Washington DC, 2010; 431-438.
32. Kemball C, Fujinami RS, Whitton JL. Adaptive immune responses. In: The Picornaviruses, Ehrenfeld E, Domingo E, Roos R (eds). ASM Press, Washington, D.C., 2010; 303-319.
33. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV, Jr.. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 1985; 314: 548-550.
34. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 1994; 12: 503-507.
35. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192: 18-26.
36. Nomoto A, Toyoda H, Imura N. Comparative sequence analysis of the 5'terminal noncoding regions of poliovirus vaccine strain Sabin 1, Sabin 2, and Sabin 3 genomes. Virology 1981; 113: 54-63.
37. Chapman NM, Tu Z, Tracy S, Gauntt CJ. An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses. Archives of Virology 1994; 135: 115-130.
38. Chapman NM, Ragland A, Leser JS, Hofling K, Willian S, Semler BL, Tracy S. A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice. Journal of Virology 2000; 74: 4047-4056.
39. Dunn JJ, Chapman NM, Tracy S, Romero JR. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region. Journal of Virology 2000; 74: 4787-4794.
40. Iizuka N, Kohara M, Hagino-Yamagishi K, Abe S, Komatsu T, Tago K, Arita M, Nomoto A. Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding sequence of the genome. Journal of Virology 1989; 63: 5354-5363.
41. Kim KS, Tracy S, Tapprich W, Bailey J, Lee CK, Kim K, Barry WH, Chapman NM. 5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. Journal of Virology 2005; 79: 7024-7041.
42. Kuge S, Nomoto A. Construction of viable deletion and insertion mutants of the Sabin strain of type 1 poliovirus: function of the 5' noncoding sequence in viral replication. Journal of Virology 1987; 61: 1478-1487.
43. Willian S, Tracy S, Chapman N, Leser S, Romero J, Shapiro B, Currey K. Mutations in a conserved enteroviral RNA oligonucleotide sequence affect positive strand viral RNA synthesis. Archives of Virology 2000; 145: 2061-2086.
44. Chapman NM, Kim KS, Tracy S, Jackson J, Hofling K, Leser JS, Malone J, Kolbeck P. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. Journal of Virology 2000; 74: 7952-7962.
45. Hofling K, Tracy S, Chapman N, Kim KS, Smith Leser J. Expression of an antigenic adenovirus epitope in a group B coxsackievirus. Journal of Virology 2000; 74: 4570-4578.
46. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nature Reviews Immunology 2004; 4: 989-997.
47. Tirabassi RS, Guberski DL, Blankenhorn EP, Leif JH, Woda BA, Liu Z, Winans D, Greiner DL, Mordes JP. Infection with viruses from several families triggers autoimmune diabetes in LEW*1WR1 rats: prevention of diabetes by maternal immunization. Diabetes 2010; 59: 110-118.
48. van der Werf N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes/Metabolism Research and Reviews 2007; 23: 169-183.
49. Drescher KM, Kono K, Bopegamage S, Carson SD, Tracy S. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection. Virology 2004; 329: 381-394.
50. Kanno T, Kim K, Kono K, Drescher KM, Chapman NM, Tracy S. Group B coxsackievirus diabetogenic phenotype correlates with replication efficiency. Journal of Virology 2006; 80: 5637-5643.
51. Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, Lane PH, Romero JR, Leser JS. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. Journal of Virology 2002; 76: 12097-12111.
52. Tracy S, Drescher KM. Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes. Annals of the New York Academy of Sciences 2007; 1103: 143-151.
53. Tracy S, Drescher KM, Jackson JD, Kim K, Kono K. Enteroviruses, type 1 diabetes and hygiene: a complex relationship. Reviews in Medical Virology 2010; 20: 106-116.
54. Tracy S, Drescher KM, Chapman NM. Enteroviruses and type 1 diabetes. Diabetes/Metabolism Research and Reviews 2011; 27: 820-823.
55. Ahmad N, Abraham AA. Pancreatic isleitis with coxsackie virus B5 infection. Human Pathology 1982; 13: 661-662.
56. Al-Hello H, Paananen A, Eskelinen M, Ylipaasto P, Hovi T, Salmela K, Lukashev AN, Bobegamage S, Roivainen M. An enterovirus strain isolated from diabetic child belongs to a genetic subcluster of echovirus 11, but is also neutralised with monotypic antisera to coxsackievirus A9. The Journal of General Virology 2008; 89: 1949-1959.
57. Champsaur H, Dussaix E, Samolyk D, Fabre M, Bach C, Assan R. Diabetes and Coxsackie virus B5 infection. Lancet 1980; 1: 251.
58. Chehadeh W, Weill J, Vantyghem MC, Alm G, Lefebvre J, Wattre P, Hober D. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. The Journal of Infectious Diseases 2000; 181: 1929-1939.
59. Maria H, Elshebani A, Orn A, Tuvemo T, Frisk G. Simultaneous type 1 diabetes onset in mother and son coincident with an enteroviral infection. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2005; 33: 158-167.
60. Mirkovic RR, Varma KS, Yoon JW. Incidence of coxsackievirus B type 4 (CB4) infections concomitant with onset of insulin-dependent diabetes mellitus. Journal of Medical Virology 1984; 14: 9-16.
61. Nigro G, Pacella ME, Patane E, Midulla M. Multi-system coxsackievirus B-6 infection with findings suggestive of diabetes mellitus. European Journal of Pediatrics 1986; 145: 557-559.
62. Smith CP, Clements GB, Riding MH, Collins P, Bottazzo GF, Taylor KW. Simultaneous onset of type 1 diabetes mellitus in identical infant twins with enterovirus infection. Diabetic medicine: a journal of the British Diabetic Association 1998; 15: 515-517.
63. Sussman ML, Strauss L, Hodes HL. Fatal coxsackie group B virus infection in the newborn; report of a case with necropsy findings and brief review of the literature. AMA journal of diseases of children 1959; 97: 483-492.
64. Ujevich MM, Jaffe R. Pancreatic islet cell damage. Its occurrence in neonatal coxsackievirus encephalomyocarditis. Archives of pathology & laboratory medicine 1980; 104: 438-441.
65. Vreugdenhil GR, Schloot NC, Hoorens A, Rongen C, Pipeleers DG, Melchers WJ, Roep BO, Galama JM. Acute onset of type I diabetes mellitus after severe echovirus 9 infection: putative pathogenic pathways. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2000; 31: 1025-1031.
66. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. The New England Journal of Medicine 1979; 300: 1173-1179.
67. Laios K, Karamanou M, Saridaki Z, Androutsos G. Aretaeus of Cappadocia and the first description of diabetes. Hormones (Athens, Greece) 2012; 11: 109-113.
68. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51: 3353-3361.
69. Viskari HR, Koskela P, Lonnrot M, Luonuansuu S, Reunanen A, Baer M, Hyoty H. Can enterovirus infections explain the increasing incidence of type 1 diabetes? Diabetes Care 2000; 23: 414-416.
70. Drescher KM, Tracy SM. The CVB and etiology of type 1 diabetes. Current Topics in Microbiology and Immunology 2008; 323: 259-274.
71. Larsson PG, Lakshmikanth T, Svedin E, King C, Flodstrom-Tullberg M. Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice. Diabetologia 2013; 56: 867-874.
72. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383: 69-82.
73. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999; 22: 478-483.
74. Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG. Non-antigenic and antigenic interventions in type 1 diabetes. Human vaccines & immunotherapeutics 2013; 10.
75. Singer BD, King LS, D'Alessio FR. Regulatory T Cells as Immunotherapy. Frontiers in Immunology 2014; 5: 46.
76. Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, Musset L, Herson S, Klatzmann D, Benveniste O. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. The American Journal of Pathology 2009; 174: 989-998.
77. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, Campagnolo DI, Shi FD, Vollmer TL. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clinical immunology (Orlando, Fla) 2007; 125: 34-42.
78. Martinez X, Kreuwel HT, Redmond WL, Trenney R, Hunter K, Rosen H, Sarvetnick N, Wicker LS, Sherman LA. CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles. Journal of immunology (Baltimore, Md: 1950) 2005; 175: 1677-1685.
79. Morris GP, Brown NK, Kong YC. Naturally-existing CD4(+)CD25(+)Foxp3(+) regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. Journal of Autoimmunity 2009; 33: 68-76.
80. O'Connor RA, Anderton SM. Multi-faceted control of autoaggression: Foxp3+ regulatory T cells in murine models of organ-specific autoimmune disease. Cellular Immunology 2008; 251: 8-18.
81. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. The Journal of Experimental Medicine 2004; 199: 1455-1465.
82. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunology 2003; 4: 330-336.
83. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics 2001; 27: 20-21.
84. Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. Journal of immunology 2006; 177: 6603-6612.
85. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genetics 2001; 27: 68-73.
86. Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N, De Prost Y, Fischer A, Goulet O, Bodemer C. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. The British Journal of Dermatology 2009; 160: 645-651.
87. Huter EN, Punkosdy GA, Glass DD, Cheng LI, Ward JM, Shevach EM. TGF-beta-induced Foxp3+ regulatory T cells rescue scurfy mice. European Journal of Immunology 2008; 38: 1814-1821.
88. Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. Journal of Clinical Immunology 2008; 28(Suppl 1): S11-19.
89. Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunological Reviews 2005; 203: 156-164.
90. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature Genetics 2001; 27: 18-20.
91. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. Journal of Clinical Immunology 2008; 28: 697-706.
92. Luczynski W, Stasiak-Barmuta A, Urban R, Urban M, Florys B, Hryszko M. Lower percentages of T regulatory cells in children with type 1 diabetes - preliminary report. Pediatric Endocrinology, Diabetes, and Metabolism 2009; 15: 34-38.
93. Szypowska A, Stelmaszczyk-Emmel A, Demkow U, Luczynski W. Low frequency of regulatory T cells in the peripheral blood of children with type 1 diabetes diagnosed under the age of five. Archivum Immunologiae et Therapiae Experimentalis 2012; 60: 307-313.
94. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. Journal of immunology (Baltimore, Md: 1950) 2008; 180: 6411-6420.
95. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clinical immunology (Orlando, Fla) 2005; 115: 3-9.
96. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58: 652-662.
97. Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatric Diabetes 2013; 14: 322-332.
98. Filippi CM, Estes EA, Oldham JE, von Herrath MG. Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. The Journal of Clinical Investigation 2009; 119: 1515-1523.
99. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual Review of Immunology 2009; 27: 485-517.
100. Smigiel KS, Srivastava S, Stolley JM, Campbell DJ. Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunological Reviews 2014; 259: 40-59.
101. Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. The Journal of Experimental Medicine 2014; 211: 961-974.
102. Baca Jones C, Pagni PP, Fousteri G, Sachithanantham S, Dave A, Rodriguez-Calvo T, Miller J, von Herrath M. Regulatory T cells control diabetes without compromising acute anti-viral defense. Clinical immunology (Orlando, Fla) 2014; 153: 298-307.
103. Bach JF, Chatenoud L. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harbor perspectives in medicine 2012; 2: a007799.
104. Strachan DP. Hay fever, hygiene, and household size. BMJ (Clinical research ed) 1989; 299: 1259-1260.
105. Romero J, Price C, Dunn JJ. Genetic divergence among the group B coxsackieviruses. Current Topics in Microbiology and Immunology 1997; 223: 97-152.
106. Tracy S, Chapman NM, Romero J, Ramsingh AI. Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Trends in Microbiology 1996; 4: 175-179.
107. Tracy S, Hofling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. Journal of Medical Virology 2000; 62: 70-81.
108. Anagandula M, Richardson SJ, Oberste MS, Sioofy-Khojine AB, Hyoty H, Morgan NG, Korsgren O, Frisk G. Infection of human islets of langerhans with two strains of coxsackie B virus serotype 1: Assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway. Journal of Medical Virology 2014; 86: 1402-1411.
109. Jaidane H, Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes & Metabolism 2008; 34: 537-548.
110. Laitinen OH, Honkanen H, Pakkanen O, Oikarinen S, Hankaniemi MM, Huhtala H, Ruokoranta T, Lecouturier V, Andre P, Harju R, Virtanen SM, Lehtonen J, Almond JW, Simell T, Simell O, Ilonen J, Veijola R, Knip M, Hyoty H. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes 2014; 63: 446-455.
111. Eringsmark Regnell S, Lernmark A. The environment and the origins of islet autoimmunity and Type 1 diabetes. Diabetic medicine: a journal of the British Diabetic Association 2013; 30: 155-160.
112. Lee HS, Briese T, Winkler C, Rewers M, Bonifacio E, Hyoty H, Pflueger M, Simell O, She JX, Hagopian W, Lernmark A, Akolkar B, Krischer JP, Ziegler AG. Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Diabetologia 2013; 56: 1705-1711.
113. Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, Rowe P, Moraski JM, Ball S, Jebson L, Schatz DA, Gianani R, Burke GW, Nierras C, Staeva T, Kaddis JS, Campbell-Thompson M, Atkinson MA. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatric Diabetes 2014; 15: 1-9.
114. Cooke A. Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology 2009; 126: 12-17.
115. Zaccone P, Hall SW. Helminth infection and type 1 diabetes. The review of diabetic studies: RDS 2012; 9: 272-286.
116. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyoty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011; 6: e25792.
117. Ivanov, II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498.
118. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, Normier G, Chatenoud L, Thieblemont N, Bach JF. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006; 55: 179-185.
119. Sai P, Rivereau AS. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes & Metabolism 1996; 22: 341-348.
120. Smith AD, Dawson H. Glutathione is required for efficient production of infectious picornavirus virions. Virology 2006; 353: 258-267.
121. Kim K, Kanno T, Tracy S, Chapman N. Genetic determinants of virulence in the group B coxsackieviruses. Future Virology 2006; 1: 597-604.
122. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. The Journal of Experimental Medicine 1991; 174: 791-798.
123. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annual Review of Immunology 1994; 12: 809-837.
124. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA: The Journal of the American Medical Association 2004; 292: 1696-1701.
125. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001; 107: E83.
126. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmunity Reviews 2007; 6: 315-322.
127. Coppieters KT, Harrison LC, von Herrath MG. Trials in type 1 diabetes: Antigen-specific therapies. Clinical immunology (Orlando, Fla) 2013; 149: 345-355.
128. Diana J, Brezar V, Beaudoin L, Dalod M, Mellor A, Tafuri A, von Herrath M, Boitard C, Mallone R, Lehuen A. Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. The Journal of Experimental Medicine 2011; 208: 729-745.
129. Beck MA, Tracy SM. Murine cell-mediated immune response recognizes an enterovirus group-specific antigen(s). Journal of Virology 1989; 63: 4148-4156.
130. Beck MA, Tracy SM. Evidence for a group-specific enteroviral antigen(s) recognized by human T cells. Journal of Clinical Microbiology 1990; 28: 1822-1827.
131. Graham S, Wang EC, Jenkins O, Borysiewicz LK. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. Journal of Virology 1993; 67: 1627-1637.
132. Beck MA, Tracy S, Coller BA, Chapman NM, Hufnagel G, Johnson JE, Lomonossoff G. Comoviruses and enteroviruses share a T cell epitope. Virology 1992; 186: 238-246.
133. Katrak K, Mahon BP, Minor PD, Mills KH. Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus. The Journal of General Virology 1991; 72(Pt 5): 1093-1098.
134. Landau BJ, Whittier PS, Finkelstein SD, Alstein B, Grun JB, Schultz M, Crowell RL. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microbial Pathogenesis 1990; 8: 289-298.
135. Hyoty H, Knip M. Developing a vaccine for Type 1 diabetes through targeting enteroviral infections. Expert Review of Vaccines 2014; 13: 989-999.
136. Hamalainen S, Nurminen N, Ahlfors H, Oikarinen S, Sioofy-Khojine AB, Frisk G, Oberste MS, Lahesmaa R, Pesu M, Hyoty H. Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. Journal of Medical Virology 2014; 86: 1412-1420.